Compound catalog

Weekly GLP-1 RA — pivotal A-grade evidence in T2D, obesity, and CVD risk reduction.

First dual incretin agonist — ~20% mean weight loss at 15 mg in obesity.

Daily lipidated GLP-1 RA — first agent with CV outcome benefit (LEADER, 2016).

Triagonist showing ~24% weight loss at 48 weeks in phase 2 — phase 3 ongoing.

Only FDA-approved GHRH analog — HIV-associated lipodystrophy.

Truncated GHRH — historically FDA-approved (Geref, withdrawn 2008); now compounded.

Selective ghrelin-receptor agonist with minimal cortisol/prolactin effect — no human efficacy RCTs.

DAC variant binds albumin → multi-day half-life. Not FDA-approved; widely sold grey-market.

Strong rodent healing data, essentially zero controlled human trials. FDA Cat 2 (2023).

Veterinary use exists; no FDA-approved human indication. Often co-marketed with BPC-157.

Modest A-grade evidence as a topical cosmeceutical; systemic 'anti-aging' claims are unsupported.

Encoded by mitochondrial 12S rRNA — exciting biology, no human therapeutic data.

FDA-approved for HSDD in premenopausal women; widely misused off-label for ED.

Foundational obstetric peptide — induction, augmentation, postpartum hemorrhage.

V2-selective ADH analog — central DI, nocturnal enuresis, mild hemophilia A / vWD.

Chemical castration via continuous GnRH agonism — prostate cancer, endometriosis, central precocious puberty, GAHT.

Workhorse somatostatin analog — acromegaly, NETs, variceal bleeding, refractory diarrhea.

Russian-origin nootropic — small non-blinded studies; not FDA-approved.

Sister Russian nootropic to Selank — same evidence caveats.

Decades of Russian institutional research from a single group; no FDA approval, no independent RCTs.

Even thinner literature than Epitalon — almost entirely cell-culture and rodent from one group.